More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.
Jerry Cacciotti
Advertisement
Articles by Jerry Cacciotti
The disease profiles pharma companies pursue should shape the business models that enable them to grow.
Advertisement
Latest Updated Articles
Pharm Exec 50: Growth from the Bottom UpPublished: May 1st 2012 | Updated:
Pharma's Next Top Model: Slimmer Business ModelsPublished: March 1st 2006 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
2
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
3
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
4
Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial
5
